These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24470007)

  • 1. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
    Gagliato Dde M; Gonzalez-Angulo AM; Lei X; Theriault RL; Giordano SH; Valero V; Hortobagyi GN; Chavez-Macgregor M
    J Clin Oncol; 2014 Mar; 32(8):735-44. PubMed ID: 24470007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed initiation of adjuvant chemotherapy in older women with breast cancer.
    Smith-Graziani D; Lei X; Giordano SH; Zhao H; Karuturi M; Chavez-MacGregor M
    Cancer Med; 2020 Oct; 9(19):6961-6971. PubMed ID: 32767723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer.
    Morante Z; Ruiz R; Araujo JM; Pinto JA; Cruz-Ku G; Urrunaga-Pastor D; Namuche F; Flores C; Mantilla R; Luján MG; Fuentes H; Schwarz L; Aguilar A; Neciosup S; Gómez HL
    Clin Breast Cancer; 2021 Jun; 21(3):239-246.e4. PubMed ID: 33221201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.
    Chavez-MacGregor M; Clarke CA; Lichtensztajn DY; Giordano SH
    JAMA Oncol; 2016 Mar; 2(3):322-9. PubMed ID: 26659132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
    Vaz-Luis I; Ottesen RA; Hughes ME; Mamet R; Burstein HJ; Edge SB; Gonzalez-Angulo AM; Moy B; Rugo HS; Theriault RL; Weeks JC; Winer EP; Lin NU
    J Clin Oncol; 2014 Jul; 32(20):2142-50. PubMed ID: 24888816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients.
    Cai L; Tong Y; Zhu X; Shen K; Zhu J; Chen X
    Sci Rep; 2020 Apr; 10(1):7029. PubMed ID: 32341397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
    Farolfi A; Scarpi E; Rocca A; Mangia A; Biglia N; Gianni L; Tienghi A; Valerio MR; Gasparini G; Amaducci L; Faedi M; Baldini E; Rubagotti A; Maltoni R; Paradiso A; Amadori D
    Eur J Cancer; 2015 Sep; 51(14):1874-81. PubMed ID: 26206258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study.
    Ashok Kumar P; Paulraj S; Wang D; Huang D; Sivapiragasam A
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2447-2458. PubMed ID: 33517468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
    He X; Ji J; Tian M; Esteva FJ; Hortobagyi GN; Yeung SJ
    Clin Cancer Res; 2019 Dec; 25(24):7388-7395. PubMed ID: 31515457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.
    Theriault RL; Litton JK; Mittendorf EA; Chen H; Meric-Bernstam F; Chavez-Macgregor M; Morrow PK; Woodward WA; Sahin A; Hortobagyi GN; Gonzalez-Angulo AM
    Clin Breast Cancer; 2011 Oct; 11(5):325-31. PubMed ID: 21764391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
    Pomponio MK; Keele LJ; Fox KR; Clark AS; Matro JM; Shulman LN; Tchou JC
    Breast Cancer Res Treat; 2019 Aug; 177(1):137-143. PubMed ID: 31119565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent.
    Yu KD; Fan L; Qiu LX; Ling H; Jiang YZ; Shao ZM
    Oncotarget; 2017 Jul; 8(28):46549-46556. PubMed ID: 27447963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.